Anti-MAG Neuropathy: Development of a Therapeutic Glycopolymer - Texte

zur Starseite
zur Hauptnavigation
zum Inhalt
zur Suche
zur Hilfe

Schrift Standard Fett
Login

Forschungsstelle

INNOSUISSE

Projektnummer

17485.1 PFLS-LS

Projekttitel

Anti-MAG Neuropathy: Development of a Therapeutic Glycopolymer

Projekttitel Englisch

Anti-MAG Neuropathy: Development of a Therapeutic Glycopolymer: MIP: Polyneuron Pharmaceuticals AG

Texte zu diesem Projekt

	Deutsch	Französisch	Italienisch	Englisch
Kurzbeschreibung		-	-
Abstract		-	-

Erfasste Texte

Kategorie	Text
Kurzbeschreibung (Deutsch)	Anti-MAG Neuropathy: Development of a Therapeutic Glycopolymer
Kurzbeschreibung (Englisch)	Anti-MAG Neuropathy: Development of a Therapeutic Glycopolymer: MIP: Polyneuron Pharmaceuticals AG
Abstract (Deutsch)	The aim of this project is to define preclinical lead candidates for the treatment of anti-myelin-associated\|glycoprotein (MAG) neuropathy, a disabling IgM autoantibody-mediated autoimmune disorder of the\|peripheral nervous system. Currently, there is no effective treatment and agents to block/deplete the\|pathogenic autoantibodies are of substancial clinical interest. Several lead candidates (glycopolymers) will\|be synthesized and evaluated in an animal model of the disease.
Abstract (Englisch)	The aim of this project is to define preclinical lead candidates for the treatment of anti-myelin-associated\|glycoprotein (MAG) neuropathy, a disabling IgM autoantibody-mediated autoimmune disorder of the\|peripheral nervous system. Currently, there is no effective treatment and agents to block/deplete the\|pathogenic autoantibodies are of substancial clinical interest. Several lead candidates (glycopolymers) will\|be synthesized and evaluated in an animal model of the disease.